Patents by Inventor E. Sally Ward
E. Sally Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11505585Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: November 22, 2017Date of Patent: November 22, 2022Assignees: argenx BV, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20220275035Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: February 15, 2022Publication date: September 1, 2022Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 10519247Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.Type: GrantFiled: October 31, 2014Date of Patent: December 31, 2019Assignee: Board of Regents,The University of Texas SystemInventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
-
Patent number: 10345310Abstract: Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, assessing progression and assessing therapy of cancer.Type: GrantFiled: June 9, 2016Date of Patent: July 9, 2019Assignee: The Board of Regents of the University of Texas SystemInventors: Alan Schroit, Adi Gazdar, E. Sally Ward Ober
-
Patent number: 10316073Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: December 23, 2014Date of Patent: June 11, 2019Assignees: argenx BVBA, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20180179258Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: November 22, 2017Publication date: June 28, 2018Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20170334962Abstract: The invention disclosed herein generally relates to fusion proteins for use alone or as adjuvants or antigen delivery vehicles for vaccines.Type: ApplicationFiled: May 19, 2017Publication date: November 23, 2017Inventors: E. Sally Ward Ober, Dilip K. Challa
-
Publication number: 20170146542Abstract: Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, assessing progression and assessing therapy of cancer.Type: ApplicationFiled: June 9, 2016Publication date: May 25, 2017Applicant: The Board of Regents of the University of Texas SystemInventors: Alan SCHROIT, Adi GAZDAR, E. Sally WARD OBER
-
Publication number: 20160229920Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.Type: ApplicationFiled: October 31, 2014Publication date: August 11, 2016Inventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
-
Publication number: 20150218239Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: December 23, 2014Publication date: August 6, 2015Applicants: arGEN-X B.V., The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 8834871Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.Type: GrantFiled: March 27, 2012Date of Patent: September 16, 2014Assignee: The Board of the University of Texas SystemInventor: E. Sally Ward Ober
-
Publication number: 20120195892Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.Type: ApplicationFiled: March 27, 2012Publication date: August 2, 2012Inventor: E. SALLY WARD OBER
-
Patent number: 8163881Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.Type: GrantFiled: May 31, 2006Date of Patent: April 24, 2012Assignee: The Board of Regents of the University of Texas SystemInventor: E. Sally Ward Ober
-
Patent number: 6165745Abstract: Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as T-cell variable domains, antibody Fc-hinge fragments, subfragments and mutant domains with reduced biological half lives. Methods of producing large quantities of such domains, heterodimers, and fusion proteins following expression and secretion by prokaryotic host cells are also reported. Described are single chain T-cell receptors, which are folded into .beta.-pleated sheet structures similar to those of immunoglobulin variable domains; antibody Fc and Fc-hinge domains, which have the same in vivo stability as intact antibodies; and domains engineered to have reduced half lives.Type: GrantFiled: November 17, 1994Date of Patent: December 26, 2000Assignee: Board of Regents, The University of Texas SystemInventors: E. Sally Ward, Jin-Kyoo Kim